VolitionRx Limited (NYSEAMERICAN:VNRX – Get Rating) – Research analysts at Cantor Fitzgerald boosted their FY2022 earnings per share estimates for shares of VolitionRx in a research note issued on Tuesday, November 22nd. Cantor Fitzgerald analyst R. Osborn now forecasts that the medical research company will post earnings of ($0.59) per share for the year, up from their previous estimate of ($0.62). The consensus estimate for VolitionRx’s current full-year earnings is ($0.50) per share. Cantor Fitzgerald also issued estimates for VolitionRx’s FY2023 earnings at ($0.87) EPS.
Several other equities analysts have also commented on the company. Aegis reduced their price target on VolitionRx from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 15th. Maxim Group reduced their price target on VolitionRx from $8.00 to $5.00 in a research report on Tuesday, August 23rd.
VolitionRx Price Performance
Hedge Funds Weigh In On VolitionRx
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of VolitionRx by 1.0% in the 1st quarter. BlackRock Inc. now owns 547,862 shares of the medical research company’s stock valued at $1,650,000 after purchasing an additional 5,644 shares in the last quarter. State Street Corp raised its position in shares of VolitionRx by 10.0% in the 1st quarter. State Street Corp now owns 115,323 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 10,500 shares in the last quarter. Captrust Financial Advisors raised its position in shares of VolitionRx by 316.7% in the 1st quarter. Captrust Financial Advisors now owns 25,000 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 19,000 shares in the last quarter. Cowen Prime Advisors LLC raised its position in shares of VolitionRx by 27.5% during the 3rd quarter. Cowen Prime Advisors LLC now owns 96,631 shares of the medical research company’s stock valued at $131,000 after acquiring an additional 20,831 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of VolitionRx during the 3rd quarter valued at approximately $51,000. 11.49% of the stock is owned by institutional investors and hedge funds.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.
- Get a free copy of the StockNews.com research report on VolitionRx (VNRX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.